Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1

Conditions

Wilms Tumor 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Xanthogranuloma, Juvenile 1Thyroid Neoplasms 1Pheochromocytoma 1Melanoma 1Histiocytic Sarcoma 1Central Nervous System Neoplasms 1

Interventions

Specimen Handling 3Temozolomide 2Magnetic Resonance Spectroscopy 2tipifarnib 1talazoparib 1pembrolizumab 1olaparib 1lutetium Lu 177 dotatate 1lanreotide 1copper dotatate CU-64 1Staining and Labeling 1Nivolumab 1Lutetium-177 1Lutetium 1Ipilimumab 1Contrast Media 1CTLA-4 Antigen 1Biopsy 1Axitinib 16-fluorodopamine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Pheochromocytoma × tipifarnib × Clear all
NCT04284774 2026-05-27

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
5 enrolled 9 charts
CNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Melanoma, Wilms Tumor, Neuroblastoma, Pheochromocytoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Thyroid Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡